| SEC Form 4 |
|------------|
|------------|

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | |
|--------------------------|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | |
| Estimated average burden | | | | | |
| hours per response: 0.5 | | | | | |

| n 16. Form 4 tions may con | or Form 5 | SL | | led purs | suant t | o Secti | ion 16(a | a) of the | Secu | rities Excha | nge Act of 1 | | SHIP | Estim | | verage burde | 3235-0287 en 0.5 |
|---|---|---|---|---|--|---|---|---|---|---|--|--|--|---|---|---|---|
| | | | | | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owne | | | | | |
| (Last) (First) (Middle) 44 MONTGOMERY STREET | | | | 3. Date of Earliest Transaction (Month/Day/Year) 11/02/2023 | | | | | | | | Office below) | r (give title) | | Other (below) | specify | |
| | | | | f Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| ISCO (| CA | 94104 | | | X Form Pers | | | | | | | x Form | filed by More than One Reporting | | | | |
| (| State) | (Zip) | | _ Rı | Chec | k this bo | ox to ind | licate tha | t a trar | nsaction was | made pursua | int to a coi | | ion or writter | n plan ti | hat is intende | ed to |
| | Tal | ole I - N | on-Deriv | vative | e Sec | curitio | es Ac | quire | d, Di | sposed | of, or Be | neficia | Ily Owne | d | | | |
| Dat | | | Date | • | | 2A. Deemed Execution Date, if any (Month/Day/Year) | | 3. Transaction Code (Instr. 8) | | Disposed Of (D) (Instr. 3, 4 | | (A) or 3, 4 and 5 | 5) Securit Benefic Owned | ies cially Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership | |
| | | | | | | | | Code | v | Amount | (A) or (D) | Price | Reported | | | (Instr. 4) | |
| Stock, \$0 | 0001 par value ⁽¹ | 1) | 11/02/ | 2023 | | | | Р | | 57,618 | Α | \$11.64 | 44 2,55 | 52,306 | | D ⁽²⁾ | |
| | 1 | | | | _ | | | Р | | - | | | | · | | | |
| 1 | | | | | | | | | | <u> </u> | A | | | ., | | _ | |
| 2 · · · · 1 | | | | | | | | | | | | | · | | _ | | |
| - | | | | | | | | | | | | | | · - | | - | |
| 1 Stock, 40 | | | | | Secu | rities | s Aca | | Dis | | | | | 4,032 | | | |
| | - | | (e.g., | puts, | | s, war | rrants | s, opti | ons, | converti | ble secu | urities) | | | | | |
| Conversior | Date | Execut if any | on Date, | | Transaction of Code (Instr. Der 8) Sec (A) Dis of (((Instr.) | | n of 🛛 | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | of Securities Underlying | | 8. Price of Derivative Security (Instr. 5) | derivative Securities Beneficia Owned Following Reported | e s Ily J | Ownershi Form: Direct (D) or Indirect (I) (Instr. 4 | Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisa | able | Expiration Date | Title | Amount or Number of Shares | | | | | |
| \$27.67 | | | | | | | | (6) | | 06/14/2033 | Common Stock, \$0.0001 par value | 12,000 | | 12,00 | 0 | <mark>I</mark> (5) | See footnote ⁽⁵⁾ |
| \$20 | | | | | | | | (7) | | 08/19/2030 | Common Stock, \$0.0001 par value | 40,127 | | 40,12 | 7 | <mark>I</mark> (5) | See footnote ⁽⁵⁾ |
| \$49.1 | | | | | | | | (8) | | 06/15/2031 | Common Stock, \$0.0001 par value | 20,063 | | 20,06 | 3 | <mark>I</mark> (5) | See footnote ⁽⁵⁾ |
| \$14.18 | | | | | | | | (9) | | 06/14/2032 | Common Stock, \$0.0001 par value | 12,000 | | 12,00 | 0 | I (5) | See footnote ⁽⁵⁾ |
| | | | iddle) | | _ | | | | | | | | | | | | |
| | 1.16. Form 4 (itions may contribute on the second secon | ARTNERS L P/IL (First) ITGOMERY STREET LOOR ISCO CA (State) Tal Security (Instr. 3) Stock, \$0.0001 par value ⁽¹⁾ Stock, \$0.0001 par value ⁽²⁾ Stock, \$0.0001 par value ⁽²⁾ S | n 16. Form 4 or Form 5 tions may continue. See tion 1(b). INTGOMERY STREET LOOR ISCO CA 94104 (State) (First) (Middle) TGOMERY STREET LOOR CA 94104 (State) (Zip) Table 1 - N Security (Instr. 3) Stock, \$0.0001 par value ⁽¹⁾ Stock, \$0.0001 par value ⁽¹⁾ Stoc | n 16. Form 4 or Form 5 tions may continue. See tion 1(b). (Middle) Fi ARTNERS L P/IL (First) (Middle) TGOMERY STREET COOR ISCO CA 94104 (State) (Zip) Table I - N-Deri Security (Instr. 3) Stock, \$0.0001 par value ⁽¹⁾ 11/02/ Stock, \$0.0001 par value ⁽¹⁾ 11/03/ Stock, \$0.0001 par valu | n 16. Form 4 or Form 5 are interestion and continue. See ition 1(b). Filed purs or or not Address of Reporting Person* ARTINERS L P/IL (First) (Middle) 11/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1 | 1.16. Form 4 or Form 5, and the second sector 1(b). Filed pursuant 1 Filed pursuant 1 Situation 1(b). Filed pursuant 1 ARTINERS L P/IL (First) (Middle) (First) (Middle) (TGOMERY STREET 3. Date of 11/02/20 LISCO CA 94104 (State) (Zip) Lange of the second | 1.16. Form 4 or Form 5 Filed pursuant to Section 30(0) Filed pursuant to Section 30(0) Filed pursuant to Section 30(0) ARTINERS L P/IL 2. Issuer Name (First) (Middle) (First) Middle) Table 1 - NOT-DErivative Security Sock 50.0001 par value ⁽¹⁾ 11/02/2023 (Stock, \$0.0001 par value ⁽¹⁾ 11/02/2023 Stock, \$0.0001 par value ⁽¹⁾ 11/02/2023 Stock, \$0.0001 par value ⁽¹⁾ 11/02/2023 Stock, \$0.0001 par value ⁽¹⁾ 11/03/2023 Conversion Date 5. N. 0 Date Code (msr. Soce 1 Sto | 1.16. Form 4 or Form 5. Filed pursuant to Section 16(Filed pursuant to Section 16(or Section 30(h) of the Address of Reporting Person* ARTNERS L. P/IL 3. Date of Earliest Tran (First) (Middle) TGOMERY STREET | 11.5. Form 4 or Form 5 months Section 30(h) of the investment to Section 16(a) of the investment of Section 30(h) of the investment of Section 3 | 1.16. Form 4 or Form 5 monthly. See the pursuant to Section 16(a) of the Section 30(b) of the Investment C or Section 30(b) of the Investment C or Section 30(b) of the Investment C and Address of Reporting Person ARTINERS L P/IL Field pursuant to Section 16(a) of the Section 30(b) of the Investment C or Section 30(b) of the Investment C and Comparison of the Inve | 11.16. Form 4 or Form 5 storm 40 controller. See Section 10(4) Filed pursuant to Section 10(4) of the Investment Company Volume 10(4) 11.00. Address of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol ARTINERS I. P/IL 3. Date of Earliest Transaction (Month/Day/Year) (First) (Middle) (State) (Zap) ISCO CA (State) 11/02/2023 ISCO P 13/20/202 ISCO P 13/20/202 ISCO P 11/02/20/23 | 11 E-ROW 40 FGm 5 or 2000 Distribution 1000 Distribution 10000 Distribution 1000 | naile Ford or gends Section 16(a) of the Securities Exchange Ad of 1334 reid pursuant to Section 16(a) of the Securities Exchange Ad of 1334 rol Address of Reporting Person* ARTINERS L P/IL. ((rist) (Mddla) ((rist) (Zp) (State) (Zp) 2. Transaction Securities Acquired, North/Day/Year) 5. Securities Acquired, North/Day/Year) Securities Acquired, North/Day/Year) 6. Stock, S0.0001 par value ⁽¹⁾ 11/02/2023 P Securities Acquired, North/Day/Year) 1. Stock, S0.0001 par value ⁽²⁾ 11/02/2023 P 1332,016 A 1. Stock, S0.0001 par value ⁽²⁾ 11/02/2023 P 1332,016 A \$14.06 | 11 Provide the formation of the investment Company Act of 1302 Image: Company Act of 1302 Imag | State in the output energy of any o | Bit All Electric UP of Fight Bits and Bits | Bit In an and Production Structure (In Control Contro Control Control Contro Control Contro Control Contro Control Cont |

44 MONTGOMERY STREET 40TH FLOOR

(Street)

SAN FRANCISCO CA

94104

| (City) | (State) | (Zip) |
|--|---|---|
| 1. Name and Address o BIOTECHNOL | of Reporting Person [*] OGY VALUE FI | UND L P |
| (Last) 44 MONTGOMER 40TH FLOOR | (First) Y STREET | (Middle) |
| (Street) SAN FRANCISCO |) CA | 94104 |
| (City) | (State) | (Zip) |
| 1. Name and Address o BVF I GP LLC | f Reporting Person* | |
| (Last) 44 MONTGOMER 40TH FLOOR | (First) Y STREET | (Middle) |
| (Street) SAN FRANCISCO |) CA | 94104 |
| (City) | (State) | (Zip) |
| 1. Name and Address o BIOTECHNOL | of Reporting Person [*] | UND II LP |
| (Last) 44 MONTGOMER 40TH FLOOR | (First) Y STREET | (Middle) |
| (Street) SAN FRANCISCO |) CA | 94104 |
| (City) | (State) | (Zip) |
| 1. Name and Address o BVF II GP LLC | | |
| (Last) 44 MONTGOMER 40TH FLOOR | (First) Y STREET | (Middle) |
| (0) | | |
| (Street) SAN FRANCISCO | CA | 94104 |
| | (State) | 94104 (Zip) |
| SAN FRANCISCO (City) 1. Name and Address o | (State) | (Zip) |
| SAN FRANCISCO (City) 1. Name and Address o | (State) of Reporting Person [*] Value Trading Fu (First) | (Zip) |
| SAN FRANCISCO (City) 1. Name and Address o <u>Biotechnology</u> (Last) P.O. BOX 309 UGI (Street) GRAND | (State) of Reporting Person [*] Value Trading Fu (First) LAND HOUSE | (Zip) nd OS LP (Middle) |
| SAN FRANCISCO (City) 1. Name and Address o <u>Biotechnology</u> (Last) P.O. BOX 309 UGI (Street) | (State) of Reporting Person [*] Value Trading Fu (First) | (Zip) nd OS LP |
| SAN FRANCISCO (City) 1. Name and Address of <u>Biotechnology</u> (Last) P.O. BOX 309 UGI (Street) GRAND CAYMAN (City) | (State) f Reporting Person* Value Trading Fu (First) LAND HOUSE E9 (State) | (Zip) nd OS LP (Middle) |
| SAN FRANCISCO (City) 1. Name and Address o <u>Biotechnology</u> (Last) P.O. BOX 309 UGI (Street) GRAND CAYMAN | (State) f Reporting Person* Value Trading Fu (First) LAND HOUSE E9 (State) f Reporting Person* | (Zip) nd OS LP (Middle) KY1-1104 |
| SAN FRANCISCO (City) 1. Name and Address o <u>Biotechnology</u> (Last) P.O. BOX 309 UGI (Street) GRAND CAYMAN (City) 1. Name and Address o | (State) fr Reporting Person* Value Trading Fu (First) CAND HOUSE E9 (State) of Reporting Person* OS Ltd. (First) | (Zip) nd OS LP (Middle) KY1-1104 |

| (City) | (State) | (Zip) | | | | | |
|---|----------------------------------|----------|--|--|--|--|--|
| 1. Name and Address of Reporting Person [*] <u>BVF GP HOLDINGS LLC</u> | | | | | | | |
| (Last) | (First) | (Middle) | | | | | |
| 44 MONTGOMER 40TH FLOOR | RY STREET | | | | | | |
| (Street) SAN FRANCISCO |) CA | 94104 | | | | | |
| (City) | (State) | (Zip) | | | | | |
| 1. Name and Address of <u>BVF INC/IL</u> | of Reporting Person [*] | | | | | | |
| (Last) | (First) | (Middle) | | | | | |
| 44 MONTGOMER 40TH FLOOR | RY STREET | | | | | | |
| | | | | | | | |
| (Street) SAN FRANCISCO |) CA | 94104 | | | | | |
| (City) | (State) | (Zip) | | | | | |
| 1. Name and Address of LAMPERT MA | | | | | | | |
| (Last) | (First) | (Middle) | | | | | |
| 44 MONTGOMERY STREET 40TH FLOOR | | | | | | | |
| (Street) SAN FRANCISCO |) CA | 94104 | | | | | |
| (City) | (State) | (Zip) | | | | | |

Explanation of Responses:

1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF I GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

2. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

3. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

4. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

5. Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. 6. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders.

7. The shares subject to the option have fully vested.

8. The shares subject to the option have fully vested.

9. The shares subject to the option have fully vested.

Remarks:

For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons may be deemed to be a director by deputization of the Issuer due to a member of Partners, Gorjan Hrustanovic, serving on the Board of Directors of the Issuer, and his agreement to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners.

| BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President | <u>11/06/2023</u> |
|---|-------------------|
| Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer | <u>11/06/2023</u> |
| BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer | <u>11/06/2023</u> |
| Biotechnology Value Fund II, L.P., By: BVF II GP LLC, its general partner, By: /s/ Mark | <u>11/06/2023</u> |

| <u>N. Lampert, Chief Executive</u> <u>Officer</u> | |
|---|---------------------------|
| <u>BVF II GP LLC, By: /s/ Mark</u> <u>N. Lampert, Chief Executive</u> <u>Officer</u> | <u>11/06/2023</u> |
| BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President | <u>11/06/2023</u> |
| Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President | <u>11/06/2023</u> |
| <u>BVF GP Holdings LLC, By: /s/</u> <u>Mark N. Lampert, Chief</u> <u>Executive Officer</u> | <u>11/06/2023</u> |
| <u>BVF Inc., By: /s/ Mark N.</u> <u>Lampert, President</u> | <u>11/06/2023</u> |
| <u>/s/ Mark N. Lampert</u> ** Signature of Reporting Person | <u>11/06/2023</u> Date |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.